在 生物医药 领域融资困境持续存在的背景下,本土biotech企业迎来了一场引人注目的大型并购案。2024年10月7日,港股18A公司嘉和生物发布公告,宣布与亿腾医药订立合并协议,亿腾医药将反向并购嘉和生物,合并后的新公司名称预计将改为“亿腾嘉和”。此次并购事件堪称业界瞩目的现象级交易。嘉和生物的研发能力和具有潜力的产品管线一直备受瞩目。而亿腾医药也以其出色的商业化能力和稳定的现金流在业界占有...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.